Description

Celluzyme is an enzyme blend specially designed to provide support for the intestinal track, thus discouraging the colonization of Candida albicans. Candida albicans is an opportunistic pathogen, which can cause serious infections in those with compromised immune system. Unlike animal cells, fungi are encompassed by a rather rigid cell wall, which provides protection from environmental extremes. The cell wall of Candida albicans is primary composed of branched glucose polymers (Glucans), N-acetyl-glucosamine (Chitin), and polymers of mannose (mannan) associated with proteins (mannoproteins).

Enzymes

Cellulase

Cellulase is a complex consisting of three enzymes that together convert cellulose (one of the basic components of cell walls) to glucose. Cellulase contributes to the effective breakdown of some of the specific fibrous cell walls present in grain, fruit and vegetables. It is also thought that Candida’s cell wall may be vulnerable to cellulose digestion. Theoretically, cellulose would disrupt the cell and the yeast would subsequently die.

Lysozymes

Lysozyme is an enzyme that attacks the protective cell walls of bacteria. Bacteria build a though skin of carbohydrate chain, interlocked by short peptide strands, which brace their delicate membrane against the cell’s high osmotic pressure. Lysozyme breaks these carbohydrate chains, destroying the structural integrity of the cell wall. Lysozymes acts as an anti-microbial agent, causing bacterial cell wall to burst under its own internal pressure. In addition to its effectiveness in lysing the bacterial cell wall, lysozyme also appears to be effective at damaging the cell walls of yeast, including C. albicans.

Amylase

Amylase will randomly hydrolyze the interior alpha-1, 4-glucosidic bonds of starch to release simple sugars for digestion. This enzyme works synergistically with endogenous human amylase to digest starchy foods.

Lactase

Lactase is characterized by its ability to hydrolyze lactose over a wide range of temperatures and pH. Chantilly’s lactase catalyzes the hydrolysis of the lactose beta-D-galactoside linkage liberating one mole of D-glucose and one mole of D-galactose. This enzyme works synergistically with endogenous human lactase to digest the sugars found in milk and dairy products.

Dosage Recommendations

The recommended dosage of Celluzyme is 2 capsules 2 times daily between meals.

Nutrition Raised to the Power of enzymes

Certain peptide sequences resulting from the partial digestion of gluten proteins have been linked to the exacerbation of gastrointestinal conditions caused by autism spectrum disorders and irritable bowel diseases. One of the enzyme activities required to break down these peptides has been identified as dipeptidyl peptidase IV (DPP IV). The lack of this enzyme activity in the small intestine due to the above conditions prevents the digestion of these peptide fragments. These peptide fragments, if left undigested, are thought to elicit immune responses that can inflame the lining of the small intestine. Also, in the case of autism spectrum disorders it has been postulated that these peptides have systemic effects that can cause certain symptoms of autism.

Biocore® DPP IV is a proprietary formulation of proteases providing a standardized DPP IV activity. The DPP IV activity in Biocore® DPP IV is standardized at 5000 units/g (Table 1). Biocore® DPP IV also provides 300,000 HUT/g and 85 aminopeptidase units per gram of the product. The recommended dose for Biocore® DPP IV is 100 mg. The proteases in Biocore® DPP IV are stable in the acidic environment of the stomach as shown in Figure 1.Inflammatory bowel disease (IBD) is a collection of chronic disorders that include Crohn’s disease, ulcerative colitis and celiac disease. A pro-inflammatory cytokine, tumor necrosis factor (TNF-), plays an important role in many forms of IBD. Many successful drugs for IBD like Infliximab have anti-TNFactivity. This category of drugs is expensive however; and the cost of treating a single patient per year can range from $25,000 to $30,000. These therapies also have to be administered intravenously, necessitating a visit to a medical facility each time. The mechanism of action of anti-TNF- therapies involve the binding to or cleaving of TNF-, resulting in the inactivation of the inflammatory action of TNF-. Our research has shown that the proteases in Biocore® DPP IV can selectively cleave and inactivate TNF- in vitro. We have also used an animal model of acute TNF- induced intestinal inflammation to show that the proteases in Biocore® DPP IV have significant therapeutic promise as anti TNF- agent.

*None of the statements above have been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent disease.

o u n d I n f o r m a t i o n